Search

Your search keyword '"Pellizzoni, C."' showing total 5 results
Start Over Author "Pellizzoni, C." Search Limiters Available in Library Collection
5 results on '"Pellizzoni, C."'

2. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

Author

Schoemaker, N E, primary, van Kesteren, C, additional, Rosing, H, additional, Jansen, S, additional, Swart, M, additional, Lieverst, J, additional, Fraier, D, additional, Breda, M, additional, Pellizzoni, C, additional, Spinelli, R, additional, Porro, M Grazia, additional, Beijnen, J H, additional, Schellens, J H M, additional, and ten Bokkel Huinink, W W, additional

Published
2002
Full Text
View/download PDF

3. Results from the analysis of data collected with a 50m(2) RPC carpet at YangBaJing

Author

THE ARGO YBJ COLLABORATION, G. AIELLI, R. ASSIRO, C. BACCI, B. BARTOLI, P. BERNARDINI, X. J. BI, B. BIONDO, C. BLEVE, S. BRICOLA, F. BUDANO, BUSSINO, Severino Angelo Maria, A. K. CALABRESE MELCARNE, P. CAMARRI, D. CAMPANA, Z. CAO, R. CARDARELLI, S. CATALANOTTI, S. CAVALIERE, P. CELIO, N. CHENG, P. CRETI, G. CUSUMANO, B. Z. DAI, G. DALI STAITI, DANZENGLUOBU, B. DAQUINO, E. DE MARINIS, I. DE MITRI, B. DETTORRE PIAZZOLI, M. DE VINCENZI, T. DI GIROLAMO, X. H. DING, G. DI SCIASCIO, C. F. FENG, ZHAOYANG FENG, ZHENYONG FENG, K. FRATINI, X. F. GAO, Q. B. GOU, H. H. HE, M. HE, HAIBING HU, HONGBO HU, Q. HUANG, M. IACOVACCI, I. JAMES, H. Y. JIA, LABACIREN, H. J. LI, J. Y. LI, B. LIBERTI, G. LIGUORI, C. Q. LIU, J. LIU, H. LU, G. MANCARELLA, A. MANGANO, G. MARSELLA, D. MARTELLO, S. MASTROIANNI, X. R. MENG, J. MU, L. NICASTRO, C. C. NING, M. PANAREO, L. PERRONE, C. PINO, C. PINTO, P. PISTILLI, E. ROSSI, L. SAGGESE, P. SALVINI, R. SANTONICO, P. R. SHEN, X. D. SHENG, F. SHI, C. STANESCU, A. SURDO, Y. H. TAN, P. VALLANIA, S. VERNETTO, H. WANG, YONGGANG WANG, YUNGANG WANG, C. Y. WU, H. R. WU, L. XUE, H. T. YANG, Q. Y. YANG, X. C. YANG, G. C. YU, A. F. YUAN, M. ZHA, H. M. ZHANG, J. L. ZHANG, L. ZHANG, N. J. ZHANG, P. ZHANG, X. Y. ZHANG, Y. ZHANG, ZHAXISANGZHU, X. X. ZHOL, F. R. ZHU, Q. Q. ZHU, MARI, Stefano Maria, Bacci, C., Bao, K. Z., Barone, F., Bartoli, B., Bernardini, P., Bussino, S., Calloni, E., Cao, B. Y., Cardarelli, R., Catalanotti, S., Cavaliere, A., Cavaliere, S., Cesaroni, F., Creti, P., Danzengluobu, D'ETTORRE PIAZZOLI, B., DE VINCENZI, M., DI GIROLAMO, T., DI SCIASCIO, G., Feng, Z. Y., Fu, Y., Gao, X. Y., Geng, Q. X., Guo, H. W., H. H., He, He, M., Huang, Q., Iacovacci, M., Iucci, N., Jai, H. Y., Kong, F. M., Kuang, H. H., Labaciren, Li, B., J. Y., Li, Liu, Z. Q., Lu, H., X. H., Ma, Mancarella, G., Mari, S. M., Marsella, Giovanni, Martello, Daniele, Mei, D. M., Meng, X. R., Milano, L., Mu, J., Panareo, Marco, Pellizzoni, G., Peng, Z. R., Pinto, C., Pistilli, P., Reali, E., Santonico, R., Sbarra, C., Shen, P. R., Stanescu, C., Su, J., Sun, L. R., Sun, S. C., Surdo, A., Tan, Y. H., Vernetto, S., Wang, C. R., Wang, H., Wang, H. Y., Wei, Y. N., Yang, H. T., Yao, Q. K., G. C., Yu, Yue, X. D., Yuan, A. F., Zhang, H. M., Zhang, J. L., Zhang, N. J., Zhang, T. J., Zhang, X. Y., Zhaxisangzhu, Zhaxiciren, Zhu, Q. Q., C., Bacci, K. Z., Bao, F., Barone, Bartoli, Bruno, P., Bernardini, S., Bussino, Calloni, Enrico, B. Y., Cao, R., Cardarelli, Catalanotti, Sergio, A., Cavaliere, S., Cavaliere, F., Cesaroni, P., Creti, D'ETTORRE PIAZZOLI, Benedetto, M. D., Vincenzi, DI GIROLAMO, Tristano, G. D., Sciascio, Z. Y., Feng, Y., Fu, X. Y., Gao, Q. X., Geng, H. W., Guo, M., He, Q., Huang, Iacovacci, Michele, N., Iucci, H. Y., Jai, F. M., Kong, H. H., Kuang, B., Li, Z. Q., Liu, H., Lu, G., Mancarella, S. M., Mari, G., Marsella, D., Martello, D. M., Mei, X. R., Meng, L., Milano, J., Mu, M., Panareo, C., Pellizzoni, Z. R., Peng, C., Pinto, P., Pistilli, E., Reali, R., Santonico, C., Sbarra, P. R., Shen, C., Stanescu, J., Su, L. R., Sun, S. C., Sun, A., Surdo, Y. H., Tan, S., Vernetto, C. R., Wang, H., Wang, H. Y., Wang, Y. N., Wei, H. T., Yang, Q. K., Yao, X. D., Yue, A. F., Yuan, H. M., Zhang, J. L., Zhang, N. J., Zhang, T. J., Zhang, X. Y., Zhang, Q. Q., Zhu, Piazzoli, B. D., Vincenzi, M. D., Girolamo, T. D., Sciascio, G. D., Mancarella, Giovanni, Pellizzoni, C., THE ARGO YBJ, Collaboration, G., Aielli, R., Assiro, B., Bartoli, X. J., Bi, B., Biondo, C., Bleve, S., Bricola, F., Budano, Bussino, Severino Angelo Maria, A. K., CALABRESE MELCARNE, P., Camarri, D., Campana, Z., Cao, S., Catalanotti, P., Celio, N., Cheng, G., Cusumano, B. Z., Dai, G., DALI STAITI, B., Daquino, E., DE MARINIS, I., DE MITRI, B., DETTORRE PIAZZOLI, M., DE VINCENZI, T., DI GIROLAMO, X. H., Ding, G., DI SCIASCIO, C. F., Feng, Zhaoyang, Feng, Zhenyong, Feng, K., Fratini, X. F., Gao, Q. B., Gou, Haibing, Hu, Hongbo, Hu, M., Iacovacci, I., Jame, H. Y., Jia, H. J., Li, B., Liberti, G., Liguori, C. Q., Liu, J., Liu, A., Mangano, Mari, Stefano Maria, S., Mastroianni, L., Nicastro, C. C., Ning, L., Perrone, C., Pino, E., Rossi, L., Saggese, P., Salvini, X. D., Sheng, F., Shi, P., Vallania, Yonggang, Wang, Yungang, Wang, C. Y., Wu, H. R., Wu, L., Xue, Q. Y., Yang, X. C., Yang, M., Zha, L., Zhang, P., Zhang, Y., Zhang, Zhaxisangzhu, X. X., Zhol, F. R., Zhu, Bacci, C, Bao, Kz, Barone, F, Bartoli, B, Bernardini, P, Calloni, E, Cao, By, Cardarelli, R, Catalanotti, S, Cavaliere, A, Cavaliere, S, Cesaroni, F, Creti, P, Piazzoli, Bd, De Vincenzi, M, Di Girolamo, T, Di Sciascio, G, Feng, Zy, Fu, Y, Gao, Xy, Geng, Qx, Guo, Hw, He, Hh, He, M, Huang, Q, Iacovacci, M, Iucci, N, Jai, Hy, Kong, Fm, Kuang, Hh, Li, B, Li, Jy, Liu, Zq, Lu, H, Ma, Xh, Mancarella, G, Marsella, G, Martello, D, Mei, Dm, Meng, Xr, Milano, L, Mu, J, Panareo, M, Pellizzoni, C, Peng, Zr, Pinto, C, Pistilli, P, Reali, E, Santonico, R, Sbarra, C, Shen, Pr, Stanescu, C, Su, J, Sun, Lr, Sun, Sc, Surdo, A, Tan, Yh, Vernetto, S, Wang, Cr, Wang, H, Wang, Hy, Wei, Yn, Yang, Ht, Yao, Qk, Yu, Gc, Yue, Xd, Yuan, Af, Zhang, Hm, Zhang, Jl, Zhang, Nj, Zhang, Tj, Zhang, Xy, and Zhu, Qq

Subjects
Physics, gamma ray detector, Nuclear and High Energy Physics, Shower, Air shower, Altitude, Meteorology, Data analysis, Gamma Ray Bursts, Effects of high altitude on humans, Instrumentation
Abstract

An RPC carpet covering similar to 10(4) m(2) (ARGO-YBJ experiment) will be installed in the YangBaJing Laboratory (Tibet, People's Republic of China) at an altitude of 4300 m a.s.l. A test-module of similar to 50 m(2) has been put in operation in this laboratory and about 10(6) air shower events have been collected. The RPC performance at high altitude and the carpet capability of reconstructing the shower features are presented. (C) 2000 Elsevier Science B.V. All rights reserved.

Published
2000

4. A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

Author

Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, and Twelves CJ

Subjects
Adult, Aged, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents therapeutic use, CDC2 Protein Kinase antagonists & inhibitors, CDC2 Protein Kinase metabolism, Cohort Studies, Cyclin-Dependent Kinase 2 antagonists & inhibitors, Cyclin-Dependent Kinase 2 metabolism, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 4 metabolism, Cyclin-Dependent Kinases metabolism, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Protein Kinase Inhibitors pharmacokinetics, Protein Kinase Inhibitors therapeutic use, Pyrazoles pharmacokinetics, Pyrazoles therapeutic use, Pyrroles pharmacokinetics, Pyrroles therapeutic use, Antineoplastic Agents adverse effects, Chemical and Drug Induced Liver Injury etiology, Cyclin-Dependent Kinases antagonists & inhibitors, Neoplasms drug therapy, Protein Kinase Inhibitors adverse effects, Pyrazoles adverse effects, Pyrroles adverse effects
Abstract

Background: PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. The primary objectives of this first in man study were to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended phase II dose of PHA-793887., Results: Although toxicity was acceptable at initial dose levels, PHA-793887 was poorly tolerated at doses ≥44 mg/m2. The most frequent events across all dose levels were gastrointestinal or nervous system events. DLTs were experienced by two of three patients at the dose level of 66 mg/m2, and by three of nine patients at the dose level of 44 mg/m2. In all but one patient the DLT was hepatotoxicity; fatal hepatorenal failure was seen in one patient treated at the 44 mg/ m2 dose level. There were no objective responses, but disease stabilization was observed in five patients. Over the dose range investigated, pharmacokinetic studies showed that systemic exposure to PHA-793887 increased with the dose and was time-independent. The study terminated after the enrolment of 19 patients due to the severe hepatic toxicity., Patients and Methods: Cohorts of three to six patients were treated at doses of 11, 22, 44 and 66 mg/m2 of PHA-793887 administered as 1-hour intravenous infusion on days 1, 8 and 15 in a 4-week cycle. Safety and pharmacokinetics were investigated., Conclusion: PHA-793887 induces severe, dose-related hepatic toxicity, which was not predicted by pre-clinical models and currently precludes its further clinical development.

Published
2011
Full Text
View/download PDF

5. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.

Author

Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, and Rocchetti M

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carboplatin administration & dosage, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System physiology, Estramustine administration & dosage, Estramustine blood, Humans, Male, Middle Aged, Paclitaxel administration & dosage, Paclitaxel blood, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prostatic Neoplasms drug therapy
Abstract

Purpose: The purpose is to determine a safe weekly dose of i.v. estramustine phosphate (EMP) to combine with weekly paclitaxel and monthly carboplatin in patients with advanced prostate cancer., Experimental Design: Patients with advanced prostate cancer (castrate and noncastrate) were administered escalating doses of weekly 1-h infusion of i.v. EMP (500-1000-1500 mg/m(2)) in combination with weekly paclitaxel (100 mg/m(2) over 1 h) and i.v. carboplatin (area under the curve 6 mg/ml-min every 4 weeks). Four weeks of therapy were considered one cycle. In the first three cohorts, EMP was given i.v. 3 h before paclitaxel. Cohorts 4 and 5 reversed the administration order: EMP (doses 1000-1500 mg/m(2)) was given immediately after the end of paclitaxel infusion. Plasma levels of EMP and its metabolites, estramustine and estromustine, were monitored at time 0, at 120 min, and approximately at 20, 21, and 168 h from the start of EMP infusion. Paclitaxel concentrations were determined at basal (0), 30, 60, 90, and 120 min and 18 h after the start of paclitaxel infusion, and a concentration-time curve was estimated. Pharmacokinetic evaluation was performed in cycles 1 and 2 during the first week of therapy., Results: Nineteen patients were entered on the initial three dose levels (cohorts 1-3). Dose-limiting transient hepatic toxicity was encountered in cohort 3 (EMP = 1500 mg/m(2)). An additional 13 patients were treated with paclitaxel (100 mg/m(2)) first, followed by i.v. EMP at 1000 mg/m(2) (cohort 4), and 1500 mg/m(2) (cohort 5). No dose-limiting toxicities were seen, and cohort 5 was determined safe for Phase II studies. Thromboembolic events were observed in 9% of patients (no prophylactic coumadin was used). Plasma concentrations of EMP and metabolites increased proportionally with dose. In all cohorts, there was a slight decrease in EMP and estramustine plasma concentrations between cycles 1 and 2. Although not significant, higher levels of estromustine at cycle 2 were observed in comparison to cycle 1. Decreased clearance of paclitaxel leading to higher than expected paclitaxel plasma concentrations was observed during the first cycle of therapy. Paclitaxel plasma concentrations were lower during cycle 2. In 17 patients with androgen-independent disease, 59% had >/=50% posttherapy decline in PSA and 22% showed measurable disease regression., Conclusions: The regimen of weekly i.v. EMP in combination with paclitaxel and carboplatin can be safely administered with hepatic toxicity being transient and reversible. Pharmacokinetic results suggest that EMP competitively inhibits the biotransformation of paclitaxel after the first administration. This effect is counterbalanced, after repeated administrations, by a possible induction of the metabolic system caused by EMP. Phase II testing is ongoing to evaluate the efficacy of this combination.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results